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Abstract 
Malignant peripheral nerve sheath tumors (MPNST) represent a group of highly heteroge-
neous human malignancies often with multiple histological origins, divergent differentiation 
patterns,  and  diverse  immunohistochemical  presentations.  The  differential  diagnosis  of 
MPNST from other spindle cell neoplasms poses great challenges for pathologists. This report 
provides a mini-review of these unique features associated with MPNST and also presents the 
first cases of MPNST with six differentiation patterns. 
Key words: Malignant peripheral nerve sheath tumor, Liposarcomatous; Glandular, Fibrohistio-
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A. Differentiation Patterns 
Malignant  peripheral  nerve  sheath  tumor 
(MPNST), also known as ―Malignant schwannoma‖, 
―Neurofibrosarcoma‖, or ―Neurosarcoma‖, is derived 
from Schwann cells or pluripotent cells of the neural 
crest  [1-5].  Epithelioid  or  other  heterogeneous  com-
ponents can be observed in 15% of MPNSTs [1, 2, 6]: 
the latter include rhabdomyoblasts [1, 2, 6-12], carti-
laginous [6, 13, 14], osseous [6, 12, 13] differentiations 
and,  rarely,  smooth  muscle  [13,  15],  glandular  [6, 
10-12, 16] or liposarcomatous components [6, 12, 17] 
have been reported. It is  rare that there are two or 
more heterogeneous components in a single MPNST. 
To our best knowledge, MPNST with four differenti-
ated components has been described only in one case 
[12]. Herein, we report one case of MPNST with six 
differentiated components. 
MPNSTs can be graded II, III or IV according to 
WHO classification [1]. They account for only 5% of 
malignant soft tissue tumors [1, 2, 7]. One half to two 
thirds arises from neurofibromas, often of plexiform 
neurofibromas or in the setting of neurofibromatosis 
type I, which occur frequently on the head or neck. 
The other MPNSTs arise de novo, which usually in-
volve the peripheral nerves in the buttocks or thighs, 
mostly the sciatic nerve [1].  
MPNST is generally characterized by alternating 
hypo- and hyper-cell areas or a diffuse growth pattern 
of spindle-shaped cells which are asymmetrical and 
fusiform  with  wavy  or  comma-shaped  hyperchro-
matic nuclei, arranged in palisades  or spiral shapes 
[1-3, 7, 8, 18, 19]. In about 15% of MPNSTs, epithelioid 
or heterologous differentiation can be found [1]; the 
later includes rhabdomyoblasts, smooth muscle, bone, 
cartilage, and neuroendocrine component [1-24]. The 
most common heterologous component in MPNST is 
rhabdomyoblast  differentiation  [1,  7,  8],  being  first 
reported by Masson in 1932 and named "nerve rhab-
domyoma", and later renamed by Woodruff as "ma-
lignant  triton  tumor".  Additionally,  differentiation 
into cartilage or bone is also not uncommon [6, 12-14], 
while liposarcomatous differentiation is very rare; to 
date,  only  4  cases  have  been  reported  [6,  12,  17]. 
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MPNST also has glandular structures [1, 2, 6, 10-12, 
16],  and  foci  of  neuroendocrine  differentiation  are 
often seen in glandular MPNST [1]. The combination 
with more than two components is very rare; to our 
best of known, only one MPNST case simultaneously 
with epithelioid differentiation,  rhabdomyosarcoma, 
bone, and liposarcoma has been reported [12]. In the 
present  case,  six  kinds  of  differentiation,  including 
rhabdomyosarcomatous,  chondral,  glandular,  neu-
roendocrine,  gangliocytic,  and  liposarcomatous 
components  were  observed  in  the  background  of  a 
classical  MPNST.  The  histological  changes  are  so 
complex  and  diverse  that  no  simple  definition  can 
cover such a wide range of differentiation, and a final 
diagnose of MPNST was made.  
The diagnosis of MPNST with multiple mesen-
chymal  differentiations  is  difficult,  and  sometimes 
should  be  differentiated  from  rhabdomyosarcoma, 
osteosarcoma, chondrosarcoma or liposarcoma [6]. In 
most  cases,  only  regional  or  focal  above-mentioned 
differentiation can be observed on the background of 
typical spindle-shaped tumor cells, which is easy to 
identify. However, rhabdomyosarcomatous differen-
tiation  occasionally  becomes  predominant;  differen-
tial diagnosis is very difficult, especially in pediatric 
patients; thus, the localization of the tumor and suffi-
cient sampls of the specimen are very important. 
In 5-10% of dedifferentiated liposarcomas, my-
oblasts,  cartilage,  and  osteosarcomatous  differentia-
tion  can  be  observed  [6,  9];  however,  the  predomi-
nancy is composed of malignant fibrous histiocytoma 
and/or  leiomyosarcoma,  and  the  ordinary  MPNST 
structure and epithelioid or glandular differentiations 
should not be visible, and medical history and tumor 
location are of keypoints for diagnosis. For example, 
dedifferentiated liposarcoma tends to occur in deep 
locations such as the retroperitoneal area, and some 
patients may have surgical resection history of a typ-
ical liposarcoma [6, 9]. 
Additionally, MPNST with glandular differenti-
ation must be differentiated from metastatic carcino-
ma.  In  MPNST,  the  spindle-shaped  cells  around 
glandular  differentiation  are  also  tumor  cells,  with 
thin  and  red  stained  cytoplasm,  and  wavy  or  com-
ma-shaped hyperchromatic nuclei; however, in meta-
static  carcinoma,  spindle-shaped  cells  around  the 
glandular  structures  are  often  reactive  proliferating 
fibroblasts. Full physical examination is also helpful 
for differential diagnosis.  
 MPNST is a tumor associated with an aggres-
sive  behavior  and  its  prognosis  is  poor  with  death 
occurring  in  63%,  usually  with  2-year  of  diagnosis. 
The  2-year  and  5-year  overall  survival  rate  are  re-
ported to be 57% and 39% [8], with the median sur-
vival period is 32 months [3]. Surgical resection is the 
best available option for treating MPNST [3, 7, 8, 23]. 
Relatively better prognosis can be seen in the patients 
with a superficial and smaller tumor, complete exci-
sion and/or with family history [1-3, 20, 22, 29]. But 
the prognosis is poorer in patients with rhabdomyo-
sarcomatous  differentiation,  the  2-year  and  5-year 
survival rates are 15% and 11% [8], respectively. And 
the mortality rate is increased to 79% in tumors with 
glandular differentiation [1]. In this case, MPNST re-
curred in the original location 10 months after resec-
tion, but chest CT and whole body bone scan did not 
demonstrate  metastases  in  the  lungs  or  bones.  The 
patient is still under follow-up. 
B. Immunohistochemical Features 
Some neural markers, such as S-100, CD56 and 
protein  gene  product  9.5  (PGP  9.5)  are  considered 
sensitive markers for peripheral nerve sheath tumors. 
S-100,  which  is  traditionally  regarded  as  the  best 
marker for MPNST, has limited diagnostic utility and 
is positive in only about 50-90% of the tumors [8]. In 
high grade MPNST, only scattered, if any, tumor cells 
are S-100 positive [1, 23]. On the other hand, although 
sensitive, CD56 and PGP 9.5 expression is in no way 
specific for tumors of MPNST [24]. Thereby, MPNSTs 
per  se  lack  sufficiently  specific  and  sensitive  im-
munohistochemical  marker.  Recent  studies  suggest 
that nestin, which is an intermediate filament protein, 
is more sensitive for MPNST than other neural mark-
ers (S-100, CD56 and PGP 9.5) and immunostains for 
nestin  in  combination  with  other  markers  could  be 
useful in the diagnosis of MPNST [25]. To cases with 
divergent differentiation  only typical tumor compo-
nents correspond to special immunophenotyping, as 
indicated in the present case. The spindle and glan-
dular tumor cells were positive for S-100 and nestin, 
and most spindle-shaped  cells were positive for vi-
mentin. Cytokeratin was expressed in the glandular 
region, CD56 expressed in most spindle-shaped cells 
and rosette formations, and Syn in some rosette for-
mations. Actin was positive focally, and other myo-
genic markers were negative.  
MPNST  with  glandular  differentiations  should 
be distinguished from other tumors with dual differ-
entiation such as synovial sarcoma and mesothelioma. 
Histological separation of MPNST from synovial sar-
comas  can  be  difficult  and  available  immunohisto-
chemical  markers,  such  as  S-100  and  cytokeratin, 
sometimes give rise to overlapping staining patterns. 
Immunostaining EMA/CK7 for synovial sarcoma and 
nestin/S100 for MPNST yielded high specificity and 
positive predictive values [26]. Recent study consid-
ered that expression of HMGA2 is a feature of MPNST  Journal of Cancer 2012, 3 
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but not of synovial sarcoma and immunohistochemi-
cal  staining  of  HMGA2  may  be  a  useful  marker  to 
separate MPNST from synovial sarcoma [27]. Another 
study showed the presence of SYT-SSX fusion tran-
script  analyzed  by  real-time  reverse  transcription 
polymerase chain reaction can be useful in the diag-
nosis of synovial sarcoma [28]. In MPNST goblet cells 
and neuroendocrine differentiation are often seen in 
glandular  structures,  which  are  seldom  found  in 
mesothelioma. Immunohistostaining for Calretinin, in 
combination  with  the  tumor  site,  is  also  helpful  to 
differentiate  mesothelioma  from  MPNST.  The  ex-
pression of Calretinin is uncommon in MPNST.  
C. Our new findings  
Clinical data 
A 79-year-old man was hospitalized because of 
an  enlarging  mass  in  his  left  thigh  for  2  years.  In-
traoperative findings showed that a solid subcutane-
ous  mass,  which  protruded  about  one  centimeter 
above the skin surface, closely connected to the lateral 
femoral nerve and slightly adherent to the vastus lat-
eralis  muscle.  The  tumor  mass  was  completely  re-
sected with part of skin covering on it. Previous his-
tory  of  the  patient  was  unremarkable  except  chole-
cystectomy due to cholecystitis and cholelithiasis 12 
years ago.  
Laboratory Tests 
 The surgical specimen was fixed in 10% neutral 
formalin,  routinely  processed,  paraffin  embedded, 
sectioned at 3 um thick, and stained conventionally 
with hematoxylin and eosin. For immunohistochem-
istry,  four-micrometer  sections  of  the  paraf-
fin-embedded tissues were deparaffinized, rehydrat-
ed  in  a  graded  series  of  alcohol  and  micro-
wave-treated for 10 min in the citrate buffer (pH 6.0). 
Endogenous  peroxidase  activity  was  blocked  using 
0.3% hydrogen peroxide. The tissue were processed in 
an automatic IHC staining machine using the stand-
ard protocols (Lab Vision Autostainer, Lab Vision Co., 
Fremont, CA, USA) with  DAKO Real™ EnVision™ 
Detection System (K5007, DAKO). All antibodies were 
bought from DAKO Co. The signals were visualized 
with 3-3′-diaminobenzidine and counterstained with 
Mayer's hematoxylin. The antigens are summarized in 
Table 1. 
 Immunohistochemical staining showed that the 
spindle and grandular tumor components were posi-
tive  for  S-100  (Figure  4A  and  4B).  Cytokeratin  was 
expressed in the region of epithelioid differentiation 
(Figure 5A). Most of the spindle cells were positive for 
vimentin  (Figure  5B)  and  some  positive  for  CD56 
(Figure 5C). Rosette formations areas expressed CD56 
(Figure  5D),  Syn  (Figure  5E)  and  CD99.  Actin  was 
positive focally, and other antibodies were all nega-
tive (Table 1). 
 
Table 1 Immunohistochemical reagents and results. 
Antibodies  Clone No.  Pretreatments and dilutions  Expression in different components 
SSC  chondroid  LS  RMS  E/G  NE 
S-100  multi-Clone  HP 1:2000   +    +    +  + 
nestin  GN-1401  HP 1:200  +      -  +  + 
vimentin  Vim3B4  HP 1:100  +      +  +  + 
MBP  7H11  NPT 1:100  -        -  - 
cytokeratin  AE1/AE3  NPT 1:200  -        +  + 
CD56  1B6  HP 1:150  +        +  + 
CD99  12E7  HP 1:100  +        +  + 
Syn  multi-Clone  HP 1:150  -        -  + 
CgA  5H7  NPT 1:75  -        -  - 
actin  HHF35  HP 1:100  -      +  -  - 
desmin  D33  NPT 1:100  -        -  - 
MyoD1  5.8A  GE 1:100  -        -  - 
myoglobin  MY018  GE 1:100  -        -  - 
myosin  F5D  HP 1:200  -        -  - 
SMA  1A4  HP 1:100  -        -  - 
CD34  QBEnd10  HP 1:150  -        -  - 
Bcl-2  124  HP 1:150  +/-        +  + 
MBP myelin basic protein, HP high pressure, GE gastric enzyme, NPT non- pretreatments, SSC spindle shaped cell, LS liposarcomatous, 
RMS rhabodomyosarcomatous, E/G epithelioid/glandular, NE neuroendocrine, component was not stained with any antibody.  Journal of Cancer 2012, 3 
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Figure 1. The tumor is located in the dermis without encapsulated (HE X 40). 
 
 
Figure 2. In most regions, tumor cells are arranged in bundles with red-stained and scant cytoplasm, and spindle-shaped nuclei (2A); 
tumor cells grew in storiform as that in fibrous histiocytoma (2B); glandular differentiation (2C) and neuroendcrime differentiation (2D) 
(HE X 100).  Journal of Cancer 2012, 3 
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Figure 3. In some regions of the tumor, the differentiation of cartilage (3A), rhabdomyosarcoma (3B), liposarcoma (3C), and ganglion 
cells (arrow) (3D) can be seen (HE X 100). 
 
 
Figure 4. Immunohistochemical staining for S-100 was positive in most spindle shaped (4A) (X 100) and glandular (4B) (X 100) tumor 
cells. 
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Figure 5. Immunohistochemical staining for Cytokeratin was positive in most epithelioid tumor cells and negative in the fusiform region 
(5 A) (X 100). Vimentin was positive in the majority of spindle -shaped cells, and negative in the epithelioid region (5 B) (X 100). CD56 
was positive in tumor tissue with spindle-shaped cells (5C) and neuroendocrine differentiation (5D) (X 100). Synaptophysin was positive 
in some neuroendocrine diffentiated tumor cells (5E) (X 100). 
 
 
Pathologic findings  
By  gross  examination,  the  fusiform  mass  was 
9cm × 6cm × 5cm in size and the covering skin is 8cm 
x  6cm  in  size.  The  cut  surface  revealed  two  inde-
pendent nodules of 5cm × 4.5cm × 3.5cm and 4cm × 
2cm × 1.5cm in size, respectively. Both of them were 
soft in texture, pale-gray and yellowish in colour, and 
well demarcated without encapsulation.  
Microscopically,  the  tumor  was  well  circum-
scribed without encapsulation and invaded the der-
mis and subcutis tissues (Figure 1). The tumor was 
mainly  composed  of  spindle-shaped  cells  with  thin 
and eosinophilic cytoplasms and atypical nuclei. The 
tumor cells arranged in bundles and wave pattern in 
most areas (Figure 2A), and in some areas, arranged 
radially or in whorls with abundant spoke-like struc-
tures (Figure 2B). Myxoid degeneration was visible in 
some  parts  of  the  tumor.  Epithelioid  differentiation 
with  glandular  structures  (Figure  2C)  appeared  in 
multiple foci, and rosette formation, indicating neu-
roendocrine differentiation, were also observed (Fig-
ure  2D)  in  these  areas.  Distinct  chondro- 
differentiation could be seen focally (Figure 3A). In 
some fields the tumor cells showed eosinophilic cy-
toplasms  with  eccentric  nuclei,  resembling  rhabdo-
myoblasts (Figure 3B), and in the other areas typical 
lipoblasts were also visible (Figure 3C). Ganglion cells 
were focally scattered (Figure 3D). Multiple patches of 
necrosis  were  observed.  Pathological  diagnosis  was 
MPNST  with  heterougenous  differentiations,  WHO 
grade IV. 
Follow-up  
The  patient  was  postoperatively  treated  with 
radiotherapy and chemotherapy, and 3 months later 
he  received  traditional  Chinese  medicine  treatment 
for 15 days. The tumor recurred in the original site 10 
months  after  tumor  resection.  Imaging  examination 
demonstrated muscular invasion; however, chest CT 
and whole body bone scan did not reveal any metas-
tasis.  Journal of Cancer 2012, 3 
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